UW21002
OPEN TO ACCRUAL
PII Trial of ctDNA-Guided 2nd line Adjuvant Therapy for High Risk, Stage II-III, ER+ HER2- BC (DARE)
UW22102
OPEN TO ACCRUAL
RaPhLRR: PII Ribociclib + Endocrine Tx for Recurrent, Resected HR+ HER2- Breast Cancer
A012301
OPEN TO ACCRUAL
Lotam: A Randomized, Phase III Clinical Trial Of Low-Dose Tamoxifen For Selected Patients With Molec
NRGBR009
OPEN TO ACCRUAL
Trial Evaluating Addition of Adjuvant Chemo to Ovarian Function Suppression + Endocrine Therapy
UW23102
OPEN TO ACCRUAL
Cambria-2: Adjuvant Endocrine-based Therapy of Camizestrant in ER+/HR2- Early BC
UW24126
OPEN TO ACCRUAL
Elacestrant vs Standard Endocrine Therapy in Pts with Node+, Estrogen Receptor+, HER2-, Early BC